Gardless of lymphatic vessel caliber [9]. Consistent with this observation it was found that the gene dosage of prox1 plays a role in maintaining lymphatic endothelial cell identity; loss of one copy results in aberrant lymphatic valve formation and the loss of a LEC molecular profile [36]. This suggests that the gene dosage levels of Prox1 play a critical role in maintaining LEC identity. A number of studies demonstrate that interactions between the matrix environment and endothelial cells can influence endothelial cell identity. Cooley et al. demonstrate that HUVECs transferred from a 2-D to 3-D culture system undergo a reprogramming event that trends towards a lymphatic signature, for example the upregulation of the lymphatic markers Prox1 and LYVE-1. Significantly, this transdifferentiation was attenuated when smooth muscle cells/pericytes were introduced to the co-culture [37]. Similarly, Veikkola et al. demonstrate that lymphatic signatures are suppressed in BECs both in 
vitro and in vivo when in the presence of SMCs [38]. Thus, our in vivo data is consistent with the hypothesis that interactions with SMCs do play a role in regulating vascular and lymphatic endothelial cell fate. Interestingly, it appears that phenotypic drift occurs when endothelial cells are cultured into a sustained in vitro environment without support cells, suggesting that cellular environmental factors define endothelial cell identity [39]. This further points to the importance of the matrix and support cell milieu in establishing and maintaining endothelial cell identity. The relevance of the molecular interactions described in our transgenic model provides some insight into the nature of the venous specificity associated with normal lymphatic PTH 1-34 site development. One can hypothesize that the absence of mural cells associated with the cardinal vein generates a permissive environment for early lymphatic development. In contrast, the early association of mural cells with the dorsal aorta restricts the participation of this vessel in lymphatic development. In Thiazole Orange price conclusion, the evidence points to a requirement for the measured regulation of themolecular players involved in early lymphangiogenesis, specifically those involving endothelial-mural cell interactions.Materials and Methods Ethics Statement and Generation of miceThe Sunnybrook Research Institute Animal Care and Ethics Committee approved all animals and protocols that were used (approval ID #148). The construction of the tie1 and 15755315 tie2 tTA driver transgene has been previously described [40]. Transgenic animals were produced by microinjection of the ptetOS prox1 construct into male pronuclei of E0.5 embryos at the McGill Transgenic Facility. Driver and responder transgenic animals were bred to generate bigenic embryos. Embryos were genotyped for wild type, single and double transgenics. Controls were wild type or DTs in the presence of doxycycline. Doxycycline treatment involved the addition of 100 mg/mL of doxycycline/5 sucrose in the drinking water, provided ad libitum and changed at least twice per week.Immunofluorescence and immunohistochemistryEmbryos were prepared by fixing in 4 paraformaldehyde, followed by incubation in 30 sucrose and mounted in OCT for cryosectioning. Sections were treated with 0.5 TritonX-100/ PBS and blocked in 5 BSA/10 goat serum prior to antibody incubation. Antibodies used were anti-Prox1 (102PA30, RDI), Podoplanin (clone 8.1.1), LYVE-1 (ALY7), VP16 (sc-1728, Santa Cruz Biotechno.Gardless of lymphatic vessel caliber [9]. Consistent with this observation it was found that the gene dosage of prox1 plays a role in maintaining lymphatic endothelial cell identity; loss of one copy results in aberrant lymphatic valve formation and the loss of a LEC molecular profile [36]. This suggests that the gene dosage levels of Prox1 play a critical role in maintaining LEC identity. A number of studies demonstrate that interactions between the matrix environment and endothelial cells can influence endothelial cell identity. Cooley et al. demonstrate that HUVECs transferred from a 2-D to 3-D culture system undergo a reprogramming event that trends towards a lymphatic signature, for example the upregulation of the lymphatic markers Prox1 and LYVE-1. Significantly, this transdifferentiation was attenuated when smooth muscle cells/pericytes were introduced to the co-culture [37]. Similarly, Veikkola et al. demonstrate that lymphatic signatures are suppressed in BECs both in vitro and in vivo when in the presence of SMCs [38]. Thus, our in vivo data is consistent with the hypothesis that interactions with SMCs do play a role in regulating vascular and lymphatic endothelial cell fate. Interestingly, it appears that phenotypic drift occurs when endothelial cells are cultured into a sustained in vitro environment without support cells, suggesting that cellular environmental factors define endothelial cell identity [39]. This further points to the importance of the matrix and support cell milieu in establishing and maintaining endothelial 
cell identity. The relevance of the molecular interactions described in our transgenic model provides some insight into the nature of the venous specificity associated with normal lymphatic development. One can hypothesize that the absence of mural cells associated with the cardinal vein generates a permissive environment for early lymphatic development. In contrast, the early association of mural cells with the dorsal aorta restricts the participation of this vessel in lymphatic development. In conclusion, the evidence points to a requirement for the measured regulation of themolecular players involved in early lymphangiogenesis, specifically those involving endothelial-mural cell interactions.Materials and Methods Ethics Statement and Generation of miceThe Sunnybrook Research Institute Animal Care and Ethics Committee approved all animals and protocols that were used (approval ID #148). The construction of the tie1 and 15755315 tie2 tTA driver transgene has been previously described [40]. Transgenic animals were produced by microinjection of the ptetOS prox1 construct into male pronuclei of E0.5 embryos at the McGill Transgenic Facility. Driver and responder transgenic animals were bred to generate bigenic embryos. Embryos were genotyped for wild type, single and double transgenics. Controls were wild type or DTs in the presence of doxycycline. Doxycycline treatment involved the addition of 100 mg/mL of doxycycline/5 sucrose in the drinking water, provided ad libitum and changed at least twice per week.Immunofluorescence and immunohistochemistryEmbryos were prepared by fixing in 4 paraformaldehyde, followed by incubation in 30 sucrose and mounted in OCT for cryosectioning. Sections were treated with 0.5 TritonX-100/ PBS and blocked in 5 BSA/10 goat serum prior to antibody incubation. Antibodies used were anti-Prox1 (102PA30, RDI), Podoplanin (clone 8.1.1), LYVE-1 (ALY7), VP16 (sc-1728, Santa Cruz Biotechno.
